Compelo Medical Devices - Latest industry news and analysis is using cookies

We use them to give you the best experience. If you continue using our website, we'll assume that you are happy to receive all cookies on this website.

ContinueLearn More

Medtronic Presents Clinical Results Of Drug-eluting Stent

Medtronic has released clinical results of a five-year study of Endeavor program on drug-eluting stent (DES) as a treatment for coronary artery disease at American College of Cardiology’s 59th Scientific Session.

Medtronic said that the E-Pooled analysis, which includes five-year data from the Endeavor I (E-I), Endeavor II (E-II), E-II Continued Access (CA), and Endeavor III (E-III) clinical studies, and three-year data from the Endeavor IV (E-IV) and Endeavor Pharmacokinetics (E-PK) clinical studies, demonstrates striking consistency in clinical results across multiple studies.

The E-Pooled analysis includes patients who were treated with the Endeavor DES in E-I, E-PK, E-II, E-II CA, E-III and E-IV; it uses the Medtronic Driver bare-metal stent (BMS) control arm of E-II as a comparator.

The E-Pooled analysis also includes clinical data on more than 2,100 Endeavor patients from six clinical trials distinguished by 100% patient monitoring, 100% source data verification and independent, blinded event adjudication performed at the Harvard Clinical Research Institute.

The data released are the final five-year results from the Endeavor III randomised controlled trial comparing the Endeavor DES to the Cypher DES (from Johnson & Johnson’s Cordis) with a primary angiographic endpoint of late lumen loss at eight months.

The E-III five-year results show low rates of MACE, TLR and ST for Endeavor patients which are consistent with the E-Pooled analysis. They also reveal difference in rates of CD/MI as well as a trend toward lower MACE in favor of the Endeavor DES.

E-III five-year outcomes confirm the phenomena of late catch-up in TLR with the Cypher DES: From years 1–5 of follow up, the data show a TLR increase of 86% with the Cypher DES compared to 21% with the Endeavor stent. The difference in TLR rates after the first year of patient follow up in E-III drives similar overall TLR rates at five years. Additionally, MACE increased in the Cypher patients by 173% compared to 74 % in the Endeavor patients, the company reports.

David Kandzari, co-principal investigator of E-III and E-IV of Medtronic, said: “The consistency of results across these well conducted clinical trials is remarkable. The Endeavor stent has demonstrated a very compelling safety and efficacy profile wherein there is a very low likelihood that patients treated with the Endeavor stent will experience late stent clotting or the need for a repeat procedure beyond the first year of follow up.”